← SynDRA
MITOTANE
SynDRA canonical compound SYN0017574 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | CYP11B1 |
|---|
| Mechanism of action | Anti-neoplastic agent |
|---|
| Indication | adrenal cortical carcinoma |
|---|
| Disease area | oncology |
|---|
All known targets
- CYP11A1
- CYP11B1
- ESR1
- ADORA3
- ADRA2A
- CYP3A4
- FDX1
- HTR2B
- HTR6
- SLC6A2
- SLC6A3
- SLC6A4
Mechanisms of action (all sources)
- CYP11A1 INHIBITOR
- Cytochrome P450 11A1 inhibitor
- CYP11B1 INHIBITOR
- Cytochrome P450 11B1 inhibitor
- ESR1 BINDER
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ABCB11
- NR3C1
- ESR2
- NR1I2
- PGR
- DRD2
- KCNH2
- ACAT1
- OPRD1
- NR1H4
- MLNR
- NPY1R
- NFKB1
- NFE2L2
- MPHOSPH8
- MMP9
- MMP1
- NPY2R
- MC4R
- MC5R
- OPRM1
- MC3R
- MAPT
- MAPK3
- MAPK14
- MAPK1
- MAOA
- LMNA
- LCK
- L3MBTL1
- KDM4E
- KDM4A
- HTR3A
- OPRK1
- PDE3A
- HTR2A
- PDE4D
- VDR
- TSHR
- TP53
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- ANDR
- ARNT
- CP2C9
- CP2CJ
- CP3A7
- ESRRA
- GCR
- GLI3
- KCNK3
- NF2L2
- PRGR
- RARA
- RPGF4
- RXFP1
- TACC3
Drug classes
- Antineoplastic Agents
- Antineoplastic Agents, Hormonal
- Cytochrome P450 3A4 Inducers
- Anti-neoplastic agent
- antineoplastic agent
ATC classes
- L01X · OTHER ANTINEOPLASTIC AGENTS
Cross-references
Synonyms
- LYSODREN
- Lysodren
- chloditan
- chlodithane
- lysodren
- mitotan
- opeprim
- Mitotano
- Chloditan
- Chlodithane
- Mitotan
- O,p'-ddd
- O,p'-ddd,o p'-tde
- O,p'-tde
- Opeprim
- CB-313
- NSC-38721
- Opddd
- Chlodithan
- Khloditan
- Khlodithan
- Mitotanum
- Mytotan
- Bristol-Myers Squibb Brand of Mitotane
- C 3010
- CB313
- PS694_SUPELCO
- Lysodren (TN)
- Mitotano [INN-Spanish]
- Mitotanum [INN-Latin]
- Ortho,para-DDD
- Mitotane [USAN:INN:JAN]
- O,p-DDD
- O,p-Tde
- Mitotane (JAN/USP/INN)
- O,p'-DDD
- O,p'-Dichlorodiphenyldichloroethane
- O,p'-TDE
Reported adverse events
- Albuminuria
- Dizziness
- Dyspnoea
- Hepatitis
- Hepatotoxicity
- Hypertension
- Infection
- Leukopenia
- Maculopathy
- Muscular weakness
- Opportunistic infection
- Rash
Look up MITOTANE in the interactive SynDRA portal →